Capricor Therapeutics announced positive four-year data from its HOPE-2 open-label extension trial of Deramiocel, a cell therapy for Duchenne Muscular Dystrophy. Presented at the PPMD 2025 Annual Conference, the results demonstrate sustained safety and clinical benefit in slowing disease progression. This long-term follow-up supports Deramiocel's potential as a transformative therapy for a rare, debilitating neuromuscular disease, reinforcing its developmental trajectory.